Is there a role for pharmacogenetics in the treatment of panic disorder?

Pharmacogenomics

Volumn 16, Issue 8, 2015, Pages 771-774

  Caldirola, Daniela ^a   Perna, Giampaolo ^a,b,c  

^a Hermanas Hospitalarias   (Italy)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

genetic; panic disorder; polymorphism; serotonin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

5 HT1A GENE; 5 HT2A GENE; 5 HTTLPR GENE; ALLELE; ANXIETY DISORDER; CLINICAL PRACTICE; COGNITIVE THERAPY; COMT GENE; COST BENEFIT ANALYSIS; CYP2C19 GENE; CYP2D6 GENE; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; ENDOPHENOTYPE; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; PANIC; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROMOTER REGION; PSYCHIATRIC TREATMENT; REVIEW; SLC6A4 GENE; GENETICS; PANIC DISORDER;

HUMANS; PANIC DISORDER; PHARMACOGENETICS;

EID: 84936995092     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.66     Document Type: Review

References (20)

1. Perna G, Schruers K, Alciati A, Caldirola D. Novel investigational therapeutics for panic disorder. Expert Opin. Investig. Drugs 24(4), 491-505 (2015).
2. Aoki A, Ishiguro S, Watanabe T et al. Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder. Neuropsychiatr. Dis. Treat. 10, 1793-1798 (2014).
3. Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 162B(6), 487-520 (2013).
4. Fabbri C, Minarini A, Niitsu T, Serretti A. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opin. Drug Metab. Toxicol. 10(8), 1093-1118 (2014).
5. Hamilton SP. The promise of psychiatric pharmacogenomics. Biol. Psychiatry 77(1), 29-35 (2015).
6. Strug LJ, Suresh R, Fyer AJ et al. Panic disorder is associated with the serotonin transporter gene (slc6a4) but not the promoter region (5-httlpr). Mol. Psychiatry 15(2), 166-176 (2010).
7. Unschuld PG, Ising M, Erhardt A et al. Polymorphisms in the serotonin receptor gene htr2a are associated with quantitative traits in panic disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B(4), 424-429 (2007).
8. Lonsdorf TB, Ruck C, Bergstrom J et al. The symptomatic profile of panic disorder is shaped by the 5-httlpr polymorphism. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(8), 1479-1483 (2009).
9. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 30(12), 2230-2235 (2005).
10. Saeki Y, Watanabe T, Ueda M et al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Eur. J. Clin. Pharmacol. 65(7), 685-691 (2009).
11. Ishiguro S, Watanabe T, Ueda M et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur. J. Clin. Pharmacol. 67(12), 1213-1221 (2011).
12. Kim W, Choi YH, Yoon KS, Cho DY, Pae CU, Woo JM. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(8), 1413-1418 (2006).
13. Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-ht1a receptor gene polymorphism. J. Affect. Disord. 123(1-3), 308-311 (2010).
14. Favaron E, Biffi S, Grassi M, Bellodi L, Perna G. Response to paroxetine and catecol-o-metil transferasi (comt) polymorphisms in panic disorder. Presented at: 11th National Congress of the Italian Society of Pyschopathology. Rome, Italy, March 2006.
15. Woo JM, Yoon KS, Choi YH, Oh KS, Lee YS, Yu BH. The association between panic disorder and the l/l genotype of catechol-o-methyltransferase. J. Psychiatr. Res. 38(4), 365-370 (2004).
16. Schumacher J, Kristensen AS, Wendland JR, Nothen MM, Mors O, McMahon FJ. The genetics of panic disorder. J. Med. Genet. 48(6), 361-368 (2011).
17. Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can. J. Psychiatry 59(2), 62-75 (2014).
18. Narasimhan S, Lohoff FW. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics 13(4), 441-464 (2012).
19. Reynolds GP, Mcgowan OO, Dalton CF. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br. J. Clin. Pharmacol. 77(4), 654-672 (2014).
20. Perna G, Alciati A, Prestia D, Torti T, Nemeroff CB. Is there a link between child abuse and neglect ans anxiety disorders? Minerva Psichiatrica 54(2), 137-148 (2013).